JP7475049B2 - アルコキシベンゾ五員（六員）複素環式アミン化合物およびその医薬用途 - Google Patents

アルコキシベンゾ五員（六員）複素環式アミン化合物およびその医薬用途 Download PDF

Info

Publication number
JP7475049B2
JP7475049B2 JP2020542775A JP2020542775A JP7475049B2 JP 7475049 B2 JP7475049 B2 JP 7475049B2 JP 2020542775 A JP2020542775 A JP 2020542775A JP 2020542775 A JP2020542775 A JP 2020542775A JP 7475049 B2 JP7475049 B2 JP 7475049B2
Authority
JP
Japan
Prior art keywords
formula
compound
dmso
alkoxybenzo
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512913A5 (enExample
JP2021512913A (ja
Inventor
イェ，デヨン
モ，ミングァン
ヤン，ジントン
ヂョウ，ルー
チュ，ヨン
フェイ，ジンユ
キ，シャンユー
Original Assignee
フダン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フダン ユニバーシティ filed Critical フダン ユニバーシティ
Publication of JP2021512913A publication Critical patent/JP2021512913A/ja
Publication of JP2021512913A5 publication Critical patent/JP2021512913A5/ja
Application granted granted Critical
Publication of JP7475049B2 publication Critical patent/JP7475049B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2020542775A 2018-02-07 2019-01-21 アルコキシベンゾ五員（六員）複素環式アミン化合物およびその医薬用途 Active JP7475049B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810124854.9 2018-02-07
CN201810124854.9A CN110117278B (zh) 2018-02-07 2018-02-07 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
PCT/CN2019/072468 WO2019154047A1 (zh) 2018-02-07 2019-01-21 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途

Publications (3)

Publication Number Publication Date
JP2021512913A JP2021512913A (ja) 2021-05-20
JP2021512913A5 JP2021512913A5 (enExample) 2023-01-10
JP7475049B2 true JP7475049B2 (ja) 2024-04-26

Family

ID=67519628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542775A Active JP7475049B2 (ja) 2018-02-07 2019-01-21 アルコキシベンゾ五員（六員）複素環式アミン化合物およびその医薬用途

Country Status (5)

Country Link
US (1) US11396504B2 (enExample)
EP (1) EP3750890B1 (enExample)
JP (1) JP7475049B2 (enExample)
CN (1) CN110117278B (enExample)
WO (1) WO2019154047A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN110117278B (zh) 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
CN111481548A (zh) * 2019-01-29 2020-08-04 复旦大学 4-(2,6-二氯苄氧基)-3-(3-氨基吡啶)苯并[d]异噁唑在制药中的用途
CN113616652A (zh) * 2020-05-06 2021-11-09 石家庄以岭药业股份有限公司 Sms2抑制剂在制备治疗高侵袭性乳腺癌药物中的应用
CN116854670B (zh) * 2022-03-28 2026-06-02 中国科学院上海药物研究所 一类二氢喹喔啉类选择性溴结构域识别蛋白抑制剂及其制备方法和用途
CN119320385A (zh) * 2023-07-17 2025-01-17 复旦大学 烷氧基噻吩甲酰芳胺类化合物及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530711A (ja) 2002-03-11 2005-10-13 アベンティス・ファーマ・ソシエテ・アノニム アミノインダゾール誘導体、その製造方法、医薬としての該方法の中間体の使用および該誘導体を含む医薬組成物
JP2007523937A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー インダゾール誘導体およびそれを含む医薬組成物
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
JP2008543956A (ja) 2005-06-28 2008-12-04 サノフィ−アベンティス Ｒｈｏ−キナーゼの阻害剤としてのイソキノリン誘導体
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
JP2011502958A (ja) 2007-06-19 2011-01-27 武田薬品工業株式会社 グルコキナーゼ活性化インダゾール化合物
CN101993382A (zh) 2009-08-21 2011-03-30 复旦大学 芳香胺类衍生物或其类似物及其应用
JP2017529333A (ja) 2014-08-24 2017-10-05 フダン ユニバーシティ ２−アルコキシベンゾイル芳香族アミン化合物及びその薬物の用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US5668154A (en) * 1995-06-06 1997-09-16 Hoechst Marion Roussel Inc. Pyridiniminyl-1,2-benzisoxazoles and -benzisothiazoles
ES2157442T3 (es) * 1995-06-06 2001-08-16 Aventis Pharma Inc Derivados de benzoisoxazol y de indazol, utilizados como agentes neurolepticos.
GB9914486D0 (en) * 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
JP5314244B2 (ja) * 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
CA2599992A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
US7998974B2 (en) * 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
DE102005026194A1 (de) * 2005-06-06 2006-12-07 Grünenthal GmbH Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
CA2633584A1 (en) * 2005-12-20 2007-07-05 Takeda Pharmaceutical Company Limited Glucokinase activators
ES2383101T3 (es) * 2007-01-26 2012-06-18 Basf Se Compuestos de 3-amino-1,2-bencisotiazol para combatir plagas animales II
CA2676173A1 (en) * 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
JP6661192B2 (ja) 2016-01-19 2020-03-11 国立大学法人北海道大学 Ｓｍｓ２阻害活性を有するセラミド誘導体
CN110117278B (zh) 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530711A (ja) 2002-03-11 2005-10-13 アベンティス・ファーマ・ソシエテ・アノニム アミノインダゾール誘導体、その製造方法、医薬としての該方法の中間体の使用および該誘導体を含む医薬組成物
JP2007523937A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー インダゾール誘導体およびそれを含む医薬組成物
JP2008543956A (ja) 2005-06-28 2008-12-04 サノフィ−アベンティス Ｒｈｏ−キナーゼの阻害剤としてのイソキノリン誘導体
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
JP2011502958A (ja) 2007-06-19 2011-01-27 武田薬品工業株式会社 グルコキナーゼ活性化インダゾール化合物
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
CN101993382A (zh) 2009-08-21 2011-03-30 复旦大学 芳香胺类衍生物或其类似物及其应用
JP2017529333A (ja) 2014-08-24 2017-10-05 フダン ユニバーシティ ２−アルコキシベンゾイル芳香族アミン化合物及びその薬物の用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAS Registry No.2186218-29-9，DATABASE REGISTRY [online]，Entered STN，2018年03月07日
DENG, Xiaodong et al.，Eur.J.Med.Chem.，2014年，73，1-7
MO, Mingguang et al.，J.Med.Chem.，2018年，61，8241-8254
QI, Xiang-Yu et al.，Bioorg.Med.Chem.Lett.，2017年，27，3511-3515

Also Published As

Publication number Publication date
EP3750890A1 (en) 2020-12-16
US11396504B2 (en) 2022-07-26
CN110117278B (zh) 2022-07-19
WO2019154047A1 (zh) 2019-08-15
EP3750890A4 (en) 2021-08-11
CN110117278A (zh) 2019-08-13
JP2021512913A (ja) 2021-05-20
EP3750890B1 (en) 2026-04-01
US20210032230A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
CN110117278B (zh) 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
JP7128345B2 (ja) ジアリール大員環化合物、医薬組成物及びその用途
EP2991975B1 (en) Inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof
CN116925045B (zh) 甲状腺素受体β选择性激动剂化合物、其药物组合物和用途
CN116262736B (zh) 新型氧代吡啶类化合物及其制备方法和用途
JP6644770B2 (ja) ２−アルコキシベンゾイル芳香族アミン化合物及びその薬物の用途
EP3484874B1 (en) Monocyclic heteroaryl substituted compounds
CN107879975A (zh) 组蛋白去乙酰化酶抑制剂及其应用
CN116496219A (zh) 六元并五元杂环类化合物及其药物组合物和应用
Wei et al. Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors
Angajala et al. Microwave assisted amberlite-IRA-402 (OH) ion exchange resin catalyzed synthesis of new benzoxazole scaffolds derived from antiinflammatory drugs aceclofenac and mefenamic acid as potential therapeutic agents for inflammation
CN109748914B (zh) 吡啶并嘧啶类化合物及其应用
CN113135929B (zh) 呋喃并吡啶酮酰胺化合物及其制备方法和用途
WO2019091277A1 (zh) 2-(1h-吡唑-3-基)苯酚类化合物及其应用
CN108329330B (zh) 2-苄氧苯基噁唑并吡啶类化合物及其药物用途
EP1541149A1 (en) Phosphodiesterase inhibitor
JP2025515926A (ja) ５－ピリジン－１ｈ－インダゾール系化合物、医薬組成物及び使用
CN101993382B (zh) 芳香胺类衍生物或其类似物及其应用
CN117616029B (zh) 作为Wee-1抑制剂的稠环化合物
CN105439914B (zh) 4‑氨酰基苯氧乙酰胺类化合物及其药物用途
CN113135930B (zh) 呋喃并吡啶酮咪唑化合物及其制备方法和用途
CN117751122A (zh) 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
CN118184572A (zh) 一类新型HsClpP激动剂的制备及其在抗炎抗肿瘤中的用途
CN116143708A (zh) 一种多取代苯并氮杂芳基衍生物及其用途
CN104211687B (zh) 杂环取代的吲哚并萘酮衍生物、其制备方法、药物组合物及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211013

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240409

R150 Certificate of patent or registration of utility model

Ref document number: 7475049

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150